Figure 3.

Bio-engineering strategies to enhance EV targeting to EGFR expressed on tumour cells include: (A) transfection of a donor cell with a plasmid containing anti-EGFR nanobody and glycosylphosphatidylinositol (GPI) elements and (B) a plasmid containing GE11 peptide and platelet derived growth factor receptor (PDGF) elements which would subsequently be packaged into the donor cell derived EVs. (C) Native EVs bind to the C1C2 domain of a recombinant protein containing an anti-EGFR nanobody through phospholipid phosphatidylserine (PS).